<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>73</patient-age><report-id>PHHY2012FR083592</report-id><gender>female</gender><reactions><reaction>Myocardial injury (Myocarditis)</reaction><reaction>Troponin at 132</reaction><reaction>Creatine phosphokinase (CPK) increase, with a value at 616 IU/L</reaction><reaction>BNP at 22929</reaction><reaction>Fever at 40슰C/ 38.8슰C</reaction><reaction>Hypotension with systolis blood pressure of 60 mm Hg/ 60/40 mmHg</reaction><reaction>Hypothesis of neuroleptic malignant syndrome</reaction><reaction>Fell</reaction><reaction>Suspicion of cranial traumatism</reaction><reaction>Confusion</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>LEPONEX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DEPAMIDE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>NOCTAMID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TEMESTA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>COUMADINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>INIPOMP</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LEVOTHYROX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CARDENSIEL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DUPHALAC</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DAFALGAN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CALCIDOSE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Bipolar I disorder</indication></indications><patient-age>73</patient-age><outcomes><outcome>Life Threatening</outcome><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053181_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134157</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012FR083592</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>1</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-09-24</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012FR083592</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>73</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bipolar disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Atrial fibrillation</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Aortic valve replacement</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypothyroidism</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Drug hypersensitivity</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bipolar I disorder</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Myocardial injury (Myocarditis)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Myocarditis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Myocarditis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Troponin at 132</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Troponin increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Troponin increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Creatine phosphokinase (CPK) increase, with a value at 616 IU/L</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Creatine phosphokinase increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood creatine phosphokinase increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120704</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20120707</reactionenddate>
				<reactionduration>4</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>15</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>BNP at 22929</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>BNP increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Brain natriuretic peptide increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fever at 40슰C/ 38.8슰C</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fever</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pyrexia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120703</reactionstartdate>
				<reactionenddateformat>610</reactionenddateformat>
				<reactionenddate>201207</reactionenddate>
				<reactionfirsttime>14</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypotension with systolis blood pressure of 60 mm Hg/ 60/40 mmHg</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypotension</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypotension</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120703</reactionstartdate>
				<reactionenddateformat>610</reactionenddateformat>
				<reactionenddate>201207</reactionenddate>
				<reactionfirsttime>14</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypothesis of neuroleptic malignant syndrome</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Neuroleptic malignant syndrome</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Neuroleptic malignant syndrome</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201207</reactionstartdate>
				<reactionenddateformat>610</reactionenddateformat>
				<reactionenddate>201207</reactionenddate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fell</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fall</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Fall</reactionmeddrapt>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Suspicion of cranial traumatism</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Traumatic brain injury</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Craniocerebral injury</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120703</reactionstartdate>
				<reactionfirsttime>14</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Confusion</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Confusion</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Confusional state</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120703</reactionstartdate>
				<reactionenddateformat>610</reactionenddateformat>
				<reactionenddate>201207</reactionenddate>
				<reactionfirsttime>14</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120704</testdate>
				<testname>Blood creatine phosphokinase</testname>
				<testresult>616</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120704</testdate>
				<testname>Blood creatine phosphokinase</testname>
				<testresult>616</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120707</testdate>
				<testname>Blood creatine phosphokinase</testname>
				<testresult>103</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120707</testdate>
				<testname>Blood creatine phosphokinase</testname>
				<testresult>103</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120703</testdate>
				<testname>Blood pressure</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Blood pressure systolic</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Body temperature</testname>
				<testresult>40</testresult>
				<testunit>슰C</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Body temperature</testname>
				<testresult>40</testresult>
				<testunit>슰C</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120703</testdate>
				<testname>Body temperature</testname>
				<testresult>38.8</testresult>
				<testunit>슰C</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120703</testdate>
				<testname>Body temperature</testname>
				<testresult>38.8</testresult>
				<testunit>슰C</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Brain natriuretic peptide</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Troponin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>LEPONEX</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>12.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>12.5 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bipolar I disorder</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-06-20</drugstartdate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatine phosphokinase increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatine phosphokinase increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Brain natriuretic peptide increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Brain natriuretic peptide increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Confusional state</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Confusional state</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Craniocerebral injury</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Craniocerebral injury</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fall</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fall</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocarditis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocarditis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neuroleptic malignant syndrome</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neuroleptic malignant syndrome</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Troponin increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Troponin increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>LEPONEX</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>25 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-07-05</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatine phosphokinase increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatine phosphokinase increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Brain natriuretic peptide increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Brain natriuretic peptide increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Confusional state</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Confusional state</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Craniocerebral injury</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Craniocerebral injury</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fall</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fall</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocarditis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocarditis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neuroleptic malignant syndrome</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neuroleptic malignant syndrome</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Troponin increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Troponin increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DEPAMIDE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>VALPROMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>NOCTAMID</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LORMETAZEPAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TEMESTA</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LORAZEPAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>COUMADINE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>WARFARIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>INIPOMP</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PANTOPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LEVOTHYROX</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CARDENSIEL</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>BISOPROLOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DUPHALAC</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LACTULOSE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DAFALGAN</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CALCIDOSE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CALCIUM CARBONATE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012FR083592 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from healthcare <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">professional via health </Semaphore>authorities in France (health authority no: RN20120842) on 24 Sep 2012 with follow up report received from healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>on 02 Nov 2012 with follow up report received from healthcare <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">professional via health </Semaphore>authorities in France (health authority no: RN20120842) on 06 Dec 2012: This report refers to a <Semaphore x="1387834" class="Patient Age" value="73" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="73" score="1.00" ID="">73 </Semaphore>year old </Semaphore>female patient. The patient's medical history included <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation</Semaphore>, <Semaphore x="1535650" class="AnatomicStructure" value="Aorta" score="1.00" ID="C12669">aortic </Semaphore>bio prosthesis insertion and concurrent conditions included <Semaphore x="1595179" class="Disease or Finding" value="Bipolar Disorder" score="1.00" ID="C34423">bipolar <Semaphore x="1595179" class="Disease or Finding" value="Bipolar Disorder" score="1.00" ID="C34423">disorders</Semaphore></Semaphore>
    <Semaphore x="1595179" class="Disease or Finding" value="Bipolar Disorder" score="1.00" ID="C34423">
     <Semaphore x="2900421" class="MedDRA LLT" value="Depression" score="1.00" ID="10012378">, <Semaphore x="2199286" class="Disease or Finding" value="Manic Psychosis" score="1.00" ID="C35166">manic <Semaphore x="3094452" class="MedDRA LLT" value="Major depression" score="1.00" ID="10057840">depressive </Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="2900421" class="MedDRA LLT" value="Depression" score="1.00" ID="10012378">
     <Semaphore x="3098149" class="MedDRA LLT" value="Mania" score="1.00" ID="10026749">
      <Semaphore x="2789741" class="MedDRA LLT" value="Bipolar I disorder" score="1.00" ID="10004939">
       <Semaphore x="2199286" class="Disease or Finding" value="Manic Psychosis" score="1.00" ID="C35166">
        </Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3098149" class="MedDRA LLT" value="Mania" score="1.00" ID="10026749">
     <Semaphore x="2789741" class="MedDRA LLT" value="Bipolar I disorder" score="1.00" ID="10004939">
      <Semaphore x="2199286" class="Disease or Finding" value="Manic Psychosis" score="1.00" ID="C35166">
       <Semaphore x="3094452" class="MedDRA LLT" value="Major depression" score="1.00" ID="10057840">psychosis </Semaphore></Semaphore></Semaphore></Semaphore>of delirant character, <Semaphore x="2384439" class="Disease or Finding" value="Penicillin Allergy" score="1.00" ID="C34911">allergy to <Semaphore x="1004964" class="Medicine" value="Penicillin" score="0.49" ID="280930">penicillin </Semaphore></Semaphore>and <Semaphore x="2042024" class="Disease or Finding" value="Hypothyroidism" score="1.00" ID="C26800">hypothyroidism</Semaphore>. This polymedicated patient received Leponex (<Semaphore x="385490" class="Medicine" value="Clozapine" score="0.49" ID="252210">clozapine</Semaphore>) <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="2199286" class="Disease or Finding" value="Manic Psychosis" score="1.00" ID="C35166">manic <Semaphore x="3094452" class="MedDRA LLT" value="Major depression" score="1.00" ID="10057840">depressive psychosis </Semaphore></Semaphore>(previously reported as <Semaphore x="1595179" class="Disease or Finding" value="Bipolar Disorder" score="1.00" ID="C34423">bipolar disorders</Semaphore>) from 20 Jun 2012 at a dose of 12.5mg daily with an increase to 25mg daily on an unknown date (reported as Jun/ Jul 2012). During the night from 02 Jul 2012 to 03 Jul 2012, the patient <Semaphore x="2948661" class="MedDRA LLT" value="Fall" score="1.00" ID="10016173">fell </Semaphore>and she was found on the ground with suspicion of cranial traumatism, <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension </Semaphore>at 60/40mmHg, <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever </Semaphore>at 38.8슰C and <Semaphore x="1806199" class="Disease or Finding" value="Confusion" score="1.00" ID="C37928">confusion</Semaphore>. The patient was addressed to the emergency unit. On 04 Jul 2012, the patient was hospitalized because of <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever </Semaphore>at 40 degree Celsius and <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension </Semaphore>with <Semaphore x="2600642" class="Disease or Finding" value="Systolic Hypertension" score="1.00" ID="C3823">systolic </Semaphore><Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">blood pressure </Semaphore>of 60 <Semaphore x="2239010" class="Disease or Finding" value="Morular Metaplasia of the Endometrium" score="1.00" ID="C37269">mm </Semaphore>Hg with no evident <Semaphore x="2053299" class="Disease or Finding" value="Infectious Disorder" score="1.00" ID="C26726">infectious </Semaphore>focus. The patient received probabilistic broad spectrum <Semaphore x="1531928" class="Procedure" value="Antibiotic Therapy" score="1.00" ID="C15620"><Semaphore x="122820" class="Medicine" value="Antibiotic" score="0.74" ID="299081">antibiotic </Semaphore>therapy </Semaphore>with vancomycine and gentamycin. Various <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">laboratory <Semaphore x="2013340" class="Procedure" value="Hematology Test" score="1.00" ID="C49286">tests </Semaphore></Semaphore>
    <Semaphore x="2817940" class="MedDRA LLT" value="Blood test" score="1.00" ID="10061726">
     <Semaphore x="2013340" class="Procedure" value="Hematology Test" score="1.00" ID="C49286">such as, <Semaphore x="2804598" class="MedDRA LLT" value="Blood culture" score="1.00" ID="10005485">blood </Semaphore></Semaphore>
     <Semaphore x="2819852" class="MedDRA LLT" value="Blood urine" score="1.00" ID="10005863">
      </Semaphore></Semaphore>
    <Semaphore x="2819852" class="MedDRA LLT" value="Blood urine" score="1.00" ID="10005863">
     <Semaphore x="2889932" class="MedDRA LLT" value="Culture urine" score="1.00" ID="10011638">culture</Semaphore>
     <Semaphore x="2889932" class="MedDRA LLT" value="Culture urine" score="1.00" ID="10011638">, <Semaphore x="2673030" class="AnatomicStructure" value="Urine" score="1.00" ID="C13283">urine </Semaphore></Semaphore></Semaphore>
    <Semaphore x="2889932" class="MedDRA LLT" value="Culture urine" score="1.00" ID="10011638">culture</Semaphore>, <Semaphore x="1549411" class="Procedure" value="Aspiration" score="1.00" ID="C15631">lumbar puncture</Semaphore>, legionella and pneumococcus antigen <Semaphore x="1854919" class="Procedure" value="Disease Screening" score="1.00" ID="C15419">screen</Semaphore>, viral serologies and pharyngeal <Semaphore x="1549411" class="Procedure" value="Aspiration" score="1.00" ID="C15631">aspiration </Semaphore>were performed by considering framework of <Semaphore x="2510672" class="Disease or Finding" value="Severe Sepsis" score="1.00" ID="C111915">severe <Semaphore x="3245054" class="MedDRA LLT" value="Sepsis" score="1.00" ID="10040047">sepsis</Semaphore></Semaphore>. First biological workups showed a marked <Semaphore x="1821860" class="Disease or Finding" value="Creatine Phosphokinase Increased" score="1.00" ID="C78247">creatine phosphokinase (<Semaphore x="1821860" class="Disease or Finding" value="Creatine Phosphokinase Increased" score="1.00" ID="C78247">CPK) increase</Semaphore></Semaphore>, with a value at 616 IU/L on 04 Jul 2012. On 06 Jul 2012, <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever </Semaphore>persisted. As no germ was found in the sampling and no identified source of <Semaphore x="3033151" class="MedDRA LLT" value="Infection" score="1.00" ID="10021789">infection </Semaphore>was found, hypothesis of <Semaphore x="2305823" class="Disease or Finding" value="Neuroleptic Malignant Syndrome" score="1.00" ID="C94829">neuroleptic malignant syndrome </Semaphore>was stated. Depamide, Noctamid and Leponex were discontinued. The patient's <Semaphore x="2803301" class="MedDRA LLT" value="Blood creatine normal" score="1.00" ID="10005466"><Semaphore x="1821753" class="Procedure" value="Creatine Kinase Measurement" score="1.00" ID="C64489">creatine kinase </Semaphore>was normal</Semaphore>. <Semaphore x="122820" class="Medicine" value="Antibiotic" score="0.74" ID="299081">Antibiotic </Semaphore>and antiviral <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>were also discontinued. <Semaphore x="1883661" class="Disease or Finding" value="Endocarditis" score="1.00" ID="C34582">Endocarditis </Semaphore>was ruled out. <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">Fever </Semaphore>resolved after about 3 weeks of <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>. The patient also experienced <Semaphore x="2521321" class="Disease or Finding" value="Sign" score="1.00" ID="C53458">signs </Semaphore>evoking possibly <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>induced myocardial <Semaphore x="1936632" class="Disease or Finding" value="Finding by Cause" score="0.58" ID="C36291">injury </Semaphore>(<Semaphore x="2254324" class="Disease or Finding" value="Myocarditis" score="1.00" ID="C34831">myocarditis</Semaphore>) with high <Semaphore x="1627212" class="Procedure" value="Brain Natriuretic Peptide Measurement" score="1.00" ID="C74735">BNP </Semaphore>(<Semaphore x="1627212" class="Procedure" value="Brain Natriuretic Peptide Measurement" score="1.00" ID="C74735">Brain natriuretic peptide</Semaphore>) at 22929 and <Semaphore x="3289208" class="MedDRA LLT" value="Troponin" score="1.00" ID="10061576">troponin </Semaphore>at 132. The patient's trans thoracic and trans esophageal echocardiographies were normal. Since then, Leponex was contraindicated in this patient. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with Leponex was discontinued on 05 Jul 2012 (previously reported as 06 Jul 2012). A <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="652004" class="Medicine" value="Haldol" score="0.49" ID="239548">Haldol </Semaphore>was introduced. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>was favorable. On 07 Jul 2012, <Semaphore x="2803907" class="MedDRA LLT" value="Blood creatine phosphokinase" score="1.00" ID="10005467">CPK </Semaphore>were at 103 IU/L and there was no longer <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever</Semaphore>. The seriousness criteria of the events <Semaphore x="2254324" class="Disease or Finding" value="Myocarditis" score="1.00" ID="C34831">myocarditis</Semaphore>, <Semaphore x="1627212" class="Procedure" value="Brain Natriuretic Peptide Measurement" score="1.00" ID="C74735">BNP </Semaphore>at 22929, <Semaphore x="3289208" class="MedDRA LLT" value="Troponin" score="1.00" ID="10061576">Troponin </Semaphore>at 132 and <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever </Semaphore>were reported as <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>and life threatening. A Seriousness criterion of events <Semaphore x="2305823" class="Disease or Finding" value="Neuroleptic Malignant Syndrome" score="1.00" ID="C94829">neuroleptic malignant syndrome</Semaphore>, <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension </Semaphore>was <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>and for other events not reported. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>of the events <Semaphore x="2254324" class="Disease or Finding" value="Myocarditis" score="1.00" ID="C34831">myocarditis</Semaphore>, <Semaphore x="3289208" class="MedDRA LLT" value="Troponin" score="1.00" ID="10061576">troponin </Semaphore>at 132, <Semaphore x="1627212" class="Procedure" value="Brain Natriuretic Peptide Measurement" score="1.00" ID="C74735">BNP </Semaphore>at 22929 was reported as a <Semaphore x="1803876" class="Disease or Finding" value="Complete Recovery" score="1.00" ID="C82467">complete recovery </Semaphore>with no sequelae, for events <Semaphore x="1936632" class="Disease or Finding" value="Finding by Cause" score="0.58" ID="C36291">traumatic <Semaphore x="1627096" class="Disease or Finding" value="Brain Injury" score="1.00" ID="C50440">brain injury </Semaphore></Semaphore>was not reported and for other events reported as <Semaphore x="1803876" class="Disease or Finding" value="Complete Recovery" score="1.00" ID="C82467">complete recovery </Semaphore>on Jul 2012. Causality of the events <Semaphore x="2254324" class="Disease or Finding" value="Myocarditis" score="1.00" ID="C34831">myocarditis</Semaphore>, <Semaphore x="3289208" class="MedDRA LLT" value="Troponin" score="1.00" ID="10061576">troponin </Semaphore>at 132, <Semaphore x="1627212" class="Procedure" value="Brain Natriuretic Peptide Measurement" score="1.00" ID="C74735">BNP </Semaphore>at 22929, <Semaphore x="3141218" class="MedDRA LLT" value="Neuroleptic malignant syndrome" score="1.00" ID="10029282"><Semaphore x="2305823" class="Disease or Finding" value="Neuroleptic Malignant Syndrome" score="1.00" ID="C94829">neuroleptic <Semaphore x="3019239" class="MedDRA LLT" value="Hyperthermia malignant" score="1.00" ID="10020844">malignant syndrome </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="3019239" class="MedDRA LLT" value="Hyperthermia malignant" score="1.00" ID="10020844">and <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever </Semaphore></Semaphore>was suspected with Leponex medication and for other events causality was not reported.Follow up report received from healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>on 02 Nov 2012: Updated suspect <Semaphore x="1864286" class="Disease or Finding" value="Drug Exposure" score="1.00" ID="C41362">drug details (<Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore><Semaphore x="1883294" class="Procedure" value="End-of-Life Treatment Management" score="1.00" ID="C67359">end </Semaphore></Semaphore>date).Follow up report received from healthcare <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">professional via health </Semaphore>authorities in France (health authority no: RN20120842) on 06 Dec 2012: Updated medical history, concomitant medication, suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>indication and dosage regiment, <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data and added events (<Semaphore x="1806199" class="Disease or Finding" value="Confusion" score="1.00" ID="C37928">Confusion</Semaphore>, <Semaphore x="1821860" class="Disease or Finding" value="Creatine Phosphokinase Increased" score="1.00" ID="C78247">CPK increase</Semaphore>, <Semaphore x="2948661" class="MedDRA LLT" value="Fall" score="1.00" ID="10016173">fall </Semaphore>and <Semaphore x="1936632" class="Disease or Finding" value="Finding by Cause" score="0.58" ID="C36291">traumatic <Semaphore x="1627096" class="Disease or Finding" value="Brain Injury" score="1.00" ID="C50440">brain injury</Semaphore></Semaphore>).</narrativeincludeclinical>
				<sendercomment>Based on review of available reported data as the myocarditis, hypotension and fever occurred within 1month of starting study drug there is a reasonable possibility of causal relationship for the event. Events neuroleptic malignant syndrome, fall, injury are unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>